The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Metabolic dysfunction-associated fatty liver disease is associated with increased all-cause mortality in the United States
Abstract
BACKGROUND & AIMS Recently, international experts have put forward a modified criterion to redefine nonalcoholic fatty liver disease (NAFLD) as metabolic-associated fatty liver disease (MAFLD). It is suspected that outcomes such as mortality may differ for these clinical entities. We studied the impact of MAFLD and NAFLD on the all-cause and cause-specific mortality in US adults. METHODS We analyzed data from 7,761 participants in the Third National Health and Nutrition Examination Survey and their linked mortality through 2015. NAFLD was diagnosed by ultrasonographic evidence of hepatic steatosis without other known liver diseases. MAFLD was defined based on the criteria proposed by an international expert panel. The Cox proportional hazard model was used to study all-cause mortality and cause-specific mortality between MAFLD and NAFLD with adjustments for known risk factors. RESULTS During a median follow-up of 23 years, individuals with MAFLD had a 17% higher risk for all-cause mortality (hazard ratio [HR] 1.17, 95% confidence interval [CI] 1.04-1.32). Furthermore, MAFLD was associated with a higher risk for cardiovascular mortality. NAFLD per se did not increase the risk of all-cause deaths. Individuals who met both definitions were noted to have a higher risk for all-cause mortality (HR: 1.13, 95% CI: 1.00-1.26). Also, MAFLD without NAFLD had 1.7-fold higher all-cause mortality (HR: 1.66, 95% CI: 1.19-2.32). Individuals with advanced fibrosis and MAFLD had higher estimates for all-cause mortality than those with advanced fibrosis and NAFLD. CONCLUSIONS In this US population-based study, MAFLD was associated with increased risk of all-cause mortality, while NAFLD demonstrated no association with all-cause mortality after adjusting for metabolic risk factors. LAY SUMMARY Our findings provide further support to the idea that nonalcoholic fatty liver disease (NAFLD) is a part of a broader multi-system disease that also includes obesity, diabetes, high blood pressure, and high cholesterol. Therefore, re-defining NAFLD as metabolic dysfunction-associated fatty liver disease (MAFLD) may provide a better understanding of predictors that may increase the risk of death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) · Hepatology · doi:10.1002/hep.28431 · Cited by 10,781
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Eslam, M., Newsome, P. N., Sarin, S. K., Anstee, Q. M., Targher, G., Romero-Gomez, M., Zelber-Sagi, S., Wai-Sun Wong, V., Dufour, J.-F., Schattenberg, J. M., et al. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2020.03.039 · Cited by 4,472
Wai, C.-T., Greenson, J. K., Fontana, R. J., Kalbfleisch, J. D., Marrero, J. A., Conjeevaram, H. S., & Lok, A. S.-F. (2003) · Hepatology · doi:10.1053/jhep.2003.50346 · Cited by 4,406
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,203
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29466 · Cited by 2,399
The utility of radiological imaging in nonalcoholic fatty liver disease
Saadeh, S., Younossi, Z. M., Remer, E. M., Gramlich, T., Ong, J. P., Hurley, M., Mullen, K. D., Cooper, J. N., & Sheridan, M. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.35354 · Cited by 2,110
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039
Comparison of Noninvasive Markers of Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
Shah, A. G., Lydecker, A., Murray, K., Tetri, B. N., Contos, M. J., & Sanyal, A. J. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.05.033 · Cited by 1,553
AGA technical review on nonalcoholic fatty liver disease
Sanyal, A. J. (2002) · Gastroenterology · doi:10.1053/gast.2002.36572 · Cited by 1,072
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
Self-citationLee, H., Lee, Y.-H., Kim, S. U., & Kim, H. C. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.12.022 · Cited by 463
From NAFLD to MAFLD: Implications of a Premature Change in Terminology
Younossi, Z. M., Rinella, M. E., Sanyal, A. J., Harrison, S. A., Brunt, E. M., Goodman, Z., Cohen, D. E., & Loomba, R. (2021) · Hepatology · doi:10.1002/hep.31420 · Cited by 417
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease
Loria, P., Adinolfi, L. E., Bellentani, S., Bugianesi, E., Grieco, A., Fargion, S., Gasbarrini, A., Loguercio, C., Lonardo, A., Marchesini, G., et al. (2010) · Digestive and Liver Disease · doi:10.1016/j.dld.2010.01.021 · Cited by 294
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMJ · doi:10.1136/bmj.l5367 · Cited by 254
Ruhl, C. E., & Everhart, J. E. (2005) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(05)00743-3 · Cited by 242
Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
Kim, D., Touros, A., & Kim, W. R. (2018) · Clinics in Liver Disease · doi:10.1016/j.cld.2017.08.010 · Cited by 238
Self-citationLinks between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
Lim, S., Kim, J.-W., & Targher, G. (2021) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2021.04.008 · Cited by 213
Wong, V. W.-S., Wong, G. L.-H., Woo, J., Abrigo, J. M., Chan, C. K.-M., Shu, S. S.-T., Leung, J. K.-Y., Chim, A. M.-L., Kong, A. P.-S., Lui, G. C.-Y., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.10.046 · Cited by 192
Akabame, S., Hamaguchi, M., Tomiyasu, K.-I., Tanaka, M., Kobayashi-Takenaka, Y., Nakano, K., Oda, Y., & Yoshikawa, T. (2007) · Circulation Journal · doi:10.1253/circj.72.618 · Cited by 123
Kim, D., Vazquez‐Montesino, L. M., Escober, J. A., Fernandes, C. T., Cholankeril, G. T., Loomba, R. S., Harrison, S. A., Younossi, Z. M., & Ahmed, A. (2020) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000654 · Cited by 81
Self-citationObisesan, T. O., Umar, U., Plauvoi, & Gillum (2012) · Clinical Interventions in Aging · doi:10.2147/cia.s26794 · Cited by 52
Yoo, E. R., Kim, D., Vazquez‐Montesino, L. M., Escober, J. A., Li, A. A., Tighe, S. P., Fernandes, C. T., Cholankeril, G. T., & Ahmed, A. (2020) · Liver International · doi:10.1111/liv.14374 · Cited by 51
Self-citationOn the Proposed Definition of Metabolic-Associated Fatty Liver Disease
Wong, V. W., & Kanwal, F. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.01.017 · Cited by 47
MAFLD and Cardiovascular Events: What Does the Evidence Show?
George, J., Gish, R. G., & Geier, A. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2021.02.027 · Cited by 15
Li, A. A., Ahmed, A., & Kim, D. (2019) · HepatoBiliary Surgery and Nutrition · doi:10.21037/hbsn.2018.12.10 · Cited by 9
Self-citation
Cited by
Rinella, M. E., Neuschwander-Tetri, B. A., Siddiqui, M. S., Abdelmalek, M. F., Caldwell, S., Barb, D., Kleiner, D. E., & Loomba, R. (2023) · Hepatology · doi:10.1097/hep.0000000000000323 · Cited by 2,667
Current epidemiology in hepatocellular carcinoma
Konyn, P., Ahmed, A., & Kim, D. (2021) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2021.1991792 · Cited by 280
Self-citationThe intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
Díaz, L. A., Arab, J. P., Louvet, A., Bataller, R., & Arrese, M. (2023) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-023-00822-y · Cited by 207
“Importantly, MAFLD diagnostic criteria was considered to eventually help identify individuals at higher risk of adverse clinical outcomes 245,246 .”
BackgroundLiver organoids: Current advances and future applications for hepatology
Kim, Y., Kang, M., Mamo, M. G., Adisasmita, M., Huch, M., & Choi, D. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1040 · Cited by 26
Depression in nonalcoholic fatty liver disease and all-cause/cause-specific mortality
Kim, D., Manikat, R., Shaikh, A., Cholankeril, G., & Ahmed, A. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14087 · Cited by 17
Self-citation
Metadata
- Authors
- Kim, D., Konyn, P., Sandhu, K. K., Dennis, B. B., Cheung, A. C., & Ahmed, A.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2021-12
- Volume
- 75
- Issue
- 6
- Pages
- 1284-1291
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W3190321126
- Cited by
- 412
- References
- 28
- FWCI
- 49.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.